Evidence for a link between IGF-I and cancer

European Journal of Endocrinology

Volumn 151, Issue SUPPL. 1, 2004, Pages

  Jenkens, Paul J ^b   Bustin, Stephen A ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; GROWTH HORMONE; HORMONE RECEPTOR BLOCKING AGENT; PEGVISOMANT; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; TAMOXIFEN;

APOPTOSIS; AUTOCRINE EFFECT; BLOOD LEVEL; BODY SIZE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; DIET; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HOMEOSTASIS; HUMAN; PARACRINE SIGNALING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; RISK FACTOR;

HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 4644224748     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.151S017     Document Type: Review

References (56)

1. Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y, Hennekens CH & Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin like growth factor (IGF)-1 and IGF-binding protein-3. Journal of the National Cancer Institute 1999 91 620-625.
2. Manousos O, Souglakos J, Bosetti C, Tzonou A, Chatzidakis V, Trichopoulos D, Adami HO & Mantzoros C. IGF-I and IGF-II in relation to colorectal cancer. International Journal of Cancer 1999 83 15-17.
3. Giovannucci E. Insulin-like growth factor-I and binding protein-3 and risk of cancer. Hormone Research 1999 51 (Suppl 3) 34-41.
4. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE & Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998 351 1393-1396.
5. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B & Pommier G. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. International Journal of Cancer 1994 57 491-497.
6. Jenkins PJ & Besser M. Clinical perspective: acromegaly and cancer: a problem. Journal of Clinical Endocrinology and Metabolism 2001 86 2935-2941.
7. Jenkins PJ, Frajese V, Jones A-M, Camacho-Hubner C, Lowe DG, Fairclough PD, Chew SL, Grossman AB, Monson JP & Besser GM. IGF-I and the development of colorectal neoplasia in acromegaly. Journal of Clinical Endocrinology and Metabolism 2000 85 3218-3221.
8. Cats A, Dullaart RP, Kleibeuker JH, Kuipers F, Sluiter WJ, Hardonk MJ & de Vries EG. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Research 1996 56 523-526.
9. Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM, Wass JA & Dowling RH. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996 38 775-783.
10. Le Roith D, Bondy C, Yakar S, Liu JL & Butler A. The somatomedin hypothesis: 2001. Endocrine Reviews 2001 22 53-74.
11. Bustin SA, Dorudi S, Phillips SM, Feakins RM & Jenkins PJ. Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumour Biology 2002 23 130-138.
12. Kao PC, Matheny AP Jr & Lang CA. Insulin-like growth factor-I comparisons in healthy twin children. Journal of Clinical Endocrinology and Metabolism 1994 78 310-312.
13. Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN & Hunter DJ. Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiology Biomarkers Prevention 2002 11 1509-1510.
14. Tajinda K, Carroll J & Roberts CT. Regulation of insulin-like growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor. Endocrinology 1999 140 4713-4724.
15. Werner H, Karnieli E, Rauscher FJ & LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. PNAS 1996 93 8318-8323.
16. Idelman G, Glaser T, Roberts CT Jr & Werner H. WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation. Journal of Biological Chemistry 2003 278 3474-3482.
17. Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr & Daniel CW. Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. PNAS 1997 94 8132-8137.
18. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, Abeno S, Kiyotoh E, Jomgeow T, Sekimoto M, Nezu R, Yoshikawa Y, Inoue Y, Hosen N, Kawakami M, Tsuboi A, Oka Y, Ogawa H, Souda S, Aozasa K, Monden M & Sugiyama H. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Science 2003 94 712-717.
19. Hiltunen MO, Koistinaho J, Alhonen L, Myohanen S, Marin S, Kosma VM, Paakkonen M & Janne J. Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome 11p in human colorectal cancer. British Journal of Cancer 1997 76 1124-1130.
20. Remacle-Bonnet MM, Garrouste FL, Heller S, Andre F, Marvaldi JL & Pommier GJ. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Research 2000 60 2007-2017.
21. Kulik G & Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Molecular and Cellular Biology 1998 18 6711-6718.
22. Burtscher I, Compagni A, Lamm GM & Christofori G. An insulin-like growth factor-mediated, phosphatidylinositol 3′ kinase-independent survival signaling pathway in beta tumor cells. Cancer Research 1999 59 3923-3926.
23. Laviola L, Giorgino F, Chow JC, Baquero JA, Hansen H, Ooi J, Zhu J, Riedel H & Smith RJ. The adapter protein Grb10 associates preferentially with the insulin receptor as compared with the IGF-I receptor in mouse fibroblasts. Journal of Clinical Investigation 1997 99 830-837.
24. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID & Belfiore A. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clinical Cancer Research 1999 5 1935-1944.
25. Shier P & Watt VM. Primary structure of a putative receptor for a ligand of the insulin family. Journal of Biological Chemistry 1989 264 14605-14608.
26. Zhang B & Roth RA. Binding properties of chimeric insulin receptors containing the cysteine-rich domain of either the insulin-like growth factor I receptor or the insulin receptor related receptor. Biochemistry 1991 30 5113-5117.
27. Playford MP, Bicknell D, Bodmer WF & Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. PNAS 2000 97 12103-12108.
28. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C & Capeau J. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001 20 252-259.
29. Akagi Y, Liu W, Zebrowski B, Xie K & Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Research 1998 58 4008-4014.
30. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM & Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. Journal of Biological Chemistry 2002 277 38205-38211.
31. Wu Y, Yakar S, Zhao L, Hennighausen L & LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Research 2002 62 1030-1035.
32. Parrizas M & LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 1997 138 1355-1358.
33. Laban C, Bustin SA & Jenkins PJ. The GH-IGF-I axis and breast cancer. Trends in Endocrinology and Metabolism 2002 14 28-34.
34. Guvakova MA & Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Research 1997 57 2606-2610.
35. Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Torrisi R, Sandri MT, Cazzaniga M, Mora S, Robertson C, Lien EA & Decensi A. Effect of low-dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Research and Treatment 2001 69 21-27.
36. Tannenbaum GS, Gurd W, Lapointe M & Pollak M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 1992 130 3395-3401.
37. Huynh HT, Tetenes E, Wallace L & Pollak M. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Research 1993 53 1727-1730.
38. Huynh H & Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochemical and Biophysical Research Communications 1994 203 253-259.
39. Stewart AJ, Johnson MD, May FE & Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. Journal of Biological Chemistry 1990 265 21172-21178.
40. Migliaccio A, Di Domenico M, Castoria G, De Falco A, Bontempo P, Nola E & Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO Journal 1996 15 1292-1300.
41. Ahmad S, Singh N & Glazer RI. Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochemical Pharmacology 1999 58 425-430.
42. Lee AV, Weng CN, Jackson JG & Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. Journal of Endocrinology 1997 152 39-47.
43. Stoica A, Saceda M, Fakhro A, Joyner M & Martin MB. Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. Journal of Cellular Biochemistry 2000 76 605-614.
44. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE & Dowsett M. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clinical Cancer Research 2003 9 524S-532S.
45. Chen TK, Smith LM, Gebhardt DK, Birrer MJ & Brown PH. Activation and inhibition of the AP-1 complex in human breast cancer cells. Molecular Carcinogenesis 1996 15 215-226.
46. Philips A, Chalbos D & Rochefort H. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. Journal of Biological Chemistry 1993 268 14103-14108.
47. Freiss G, Prebois C, Rochefort H & Vignon F. Anti-steroidal and anti-growth factor activities of anti-estrogens. Journal of Steroid Biochemistry and Molecular Biology 1990 37 777-781.
48. Freiss G, Puech C & Vignon F. Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells. Molecular Endocrinology 1998 12 568-579.
49. Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK & Benz CC. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Research 1997 57 3723-3727.
50. Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE & Westley BR. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. European Journal of Cancer 1993 29A 2256-2264.
51. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M & Benz CC. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clinical Cancer Research 1999 5 251-256.
52. Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J & Lannigan DA. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular and Cellular Biology 1998 18 1978-1984.
53. Aronica SM & Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Molecular Endocrinology 1993 7 743-752.
54. Kopchick JJ, Parkinson C, Stevens EC & Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews 2002 23 623-646.
55. Maple S, Fernandes J, Khandwala H, Scarlett JA, Davis RA, Flyvbjerg A, McCutcheon IE & Friend KE. Pegvisomant inhibits tumor growth in a syngenic model of colon cancer metastasis. Proceedings of the 83rd American Endocrine Society, Denver, USA 2001 P1218.
56. Friend KE. Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Hormone and IGF Research 2001 11 (Suppl A) S121-S123.